Last reviewed · How we verify
MABEL CTLs
At a glance
| Generic name | MABEL CTLs |
|---|---|
| Also known as | LMP, BARF-1 and EBNA1 specific cytotoxic T lymphocytes, MABEL Cytotoxic T cells |
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MABEL CTLs CI brief — competitive landscape report
- MABEL CTLs updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI